Download PDF
Thromb Haemost 1997; 77(05): 1038-1040
DOI: 10.1055/s-0038-1656103
Letter to the Editor
Schattauer GmbH Stuttgart

A Brief Review of Studies Evaluating the Adverse Effects of Aprotinin Therapy in Aortocoronary Bypass Surgery

M J Ray
1   Department of Haematology, The Prince Charles Hospital, Brisbane, Australia
,
N A Marsh
2   Research Concentration in Biomedical Research, Queensland University of Technology, Brisbane, Australia
,
K Mengerson
3   Department of Mathematics, Queensland University of Technology, Brisbane, Australia
› Author Affiliations
Further Information

Publication History

Received 09 September 1996

Accepted after resubmission 07 January 1997

Publication Date:
11 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 van der MeerJ, Hillege HL, Koostra GJ, Ascoop CAPL, Pfisterer M, van Gilst WH, Lie KI. Prevention of one-year vein-graft occlusion after aortocoronary bypass surgery: A comparison of low-dose aspirin, low-dose aspirin plus dipyramidole, and oral anticoagulant. Lancet 1993; 342: 257-264
    CrossrefPubMedGoogle Scholar
  • 2 van derMeer J, Hillege HL, Ascoop CAPL, Dunselman PHJM, Mulder BJM, van Ommen GVA, Pfisterer M, van Gilst WH, Lie KI. Aprotinin in aortocoronary bypass surgery: Increased risk of vein-graft occlusion and myocardial infarction? Supportive evidence from a retrospective study. Thromb Haemost 1996; 75: 1-3
    PubMedGoogle Scholar
  • 3 Ollivier JP. Permeability of aortocoronary bypass after 6 months. A multicentre French study. Arch Mai Coeur Vaiss 1991; 84: 537-542
    PubMedGoogle Scholar
  • 4 Cosgrove DM, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LAR, Stewart RW, McCarthy PM, Loop FD. Aprotinin therapy for reoperative myocardial revascularisation: a placebo controlled study. Ann Thorac Surg 1992; 54: 1031-1038
    CrossrefPubMedGoogle Scholar
  • 5 Najman DM, Walenga JM, Fareed J, Pifarre R. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery. Ann Thorac Surg 1993; 55: 662-666
    CrossrefPubMedGoogle Scholar
  • 6 Lass M, Welz A, Kochs M, Mayer G, Schwandt M, Hannekum A. Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy. Eur J Cardiothorac Surg 1995; 9: 206-210
    CrossrefPubMedGoogle Scholar
  • 7 Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc-Surg 1993; 105: 147-152
    PubMedGoogle Scholar
  • 8 Kalangos A, Tayyareci G, Pretre R, Pretre R, Di DioP, Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg 1994; 8: 651-656
    CrossrefPubMedGoogle Scholar
  • 9 Lemmer JH, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, Schaff HV, Tatooles CJ, Rumberger JA. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107: 543-551
    CrossrefPubMedGoogle Scholar
  • 10 Havel M, Grabenwoger F, Schneider J, Laufer G, Wollenek G, Owen A, Simon P, Teufelsbauer H, Wolner E. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994; 107: 807-810
    PubMedGoogle Scholar
  • 11 Laub GW, Riebman JB, Chen C, Adkins MS, Anderson WA, Fernandez J, McGrath LB. The impact of aprotinin on coronary artery bypass graft patency. Chest 1994; 106: 1370-1375
    CrossrefPubMedGoogle Scholar
  • 12 Wendel HP, Heller W, Gallimore MJ, Bantel H, Muller BH, Hoffmeister HE. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coag Fibrinol 1993; 4: 41-45
    CrossrefPubMedGoogle Scholar
  • 13 Hunt BJ, Segal HC, Yacoub M. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992; 104: 211-212
    PubMedGoogle Scholar
  • 14 DerSimonian R, Laird NM. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177-188
    CrossrefPubMedGoogle Scholar
  • 15 Underwood MJ, Cooper GJ. Aprotinin and vein graft occlusion after coronary artery bypass. J Thorac Cardiovasc Surg 1995; 109: 1022
    PubMedGoogle Scholar
  • 16 van der MeerJ, Hillege HL, vanGilst WH, Brutel de la Rivière A, Dunselman PHJM, Fidler V, Koostra GJ, Mulder BJM, Pfisterer M, Lie KI. A comparison of internal mammary artery and saphenous vein grafts after coronary artery bypass: no difference in one year occlusion rates and clinical outcome. Circulation 1994; 90: 2367-2374
    CrossrefPubMedGoogle Scholar
  • 17 Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, Rosengart TK, Murray J, Clark RE, Smith P, Nadel A, Bonney SL, Kleinfield R. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92: 2236-2244
    CrossrefPubMedGoogle Scholar